{"entity":{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","aka":[],"tldr":"Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.","summary":"Approved by the NMPA in September 2021 for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, three months after the Fosun Kite import of axicabtagene ciloleucel became China's first CAR-T approval; relapsed or refractory follicular lymphoma followed in 2022. The pivotal RELIANCE study (59 patients) reported an objective response rate of 75.9% and complete responses in 51.7%, with low rates of severe cytokine release syndrome. JW Therapeutics was formed in 2016 as a joint venture between Juno Therapeutics and WuXi AppTec, and the product is the Chinese sibling of lisocabtagene maraleucel.","status":"approved","asOf":"2026-09-10","links":[{"label":"JW Therapeutics","url":"https://www.jwtherapeutics.com/en/"},{"label":"RELIANCE (Cancer Med 2021)","url":"https://doi.org/10.1002/cam4.3686"},{"label":"NMPA (National Medical Products Administration)","url":"https://www.nmpa.gov.cn"}],"tags":["china"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":["jw-therapeutics","wuxi-apptec"],"institutions":[],"pathways":[],"terms":[],"trials":["reliance","nct06093841","nct06479356"],"people":[],"bottlenecks":[],"keyPapers":["paper-ying-cancer-med"],"journals":[],"dependsOn":[],"notes":[],"brand":"Carteyva","code":"relma-cel, JWCAR029","modality":"Cell therapy (autologous CD19 CAR-T, 4-1BB)","mechanism":"Autologous T cells transduced with a CD19-directed CAR (4-1BB co-stimulatory domain) derived from the JCAR017 construct, manufactured in Shanghai by JW Therapeutics.","approvals":[{"region":"China","year":2021,"indication":"Relapsed or refractory large B-cell lymphoma after two or more lines"},{"region":"China","year":2022,"indication":"Relapsed or refractory follicular lymphoma after two or more lines"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/relmacabtagene-autoleucel/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/"},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/"}],"trial":[{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","route":"/trials/nct06479356/"},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/"},{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/"}],"paper":[{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}